Scribd Logo
Upload

Welcome to Scribd!

  • 146 views

    Lupin Pharmaceuticals Inc

    Uploaded by

    Kishor Kshirasagar
    Lupin Limited is an Indian pharmaceutical company founded in 1968. It has manufacturing facilities in 18 countries and reaches over 70 countries with its generic drugs, branded drugs, and active pharmaceutical ingredients. The company has a strong presence in therapeutic areas like asthma, pediatrics, diabetes, and CNS. It has strategically acquired companies across six continents to expand its global footprint. Some of its strengths include being a global leader in cephalosporin and anti-TB drugs, having a strong presence in over 70 countries, and being the largest generic player in the US and Japan.

    Copyright:

    © All Rights Reserved
    Download as PPTX, PDF, TXT or read online from Scribd

    Lupin Pharmaceuticals Inc

    Uploaded by

    Kishor Kshirasagar
    146 views10 pages
    Lupin Limited is an Indian pharmaceutical company founded in 1968. It has manufacturing facilities in 18 countries and reaches over 70 countries with its generic drugs, branded drugs, and active pharmaceutical ingredients. The company has a strong presence in therapeutic areas like asthma, pediatrics, diabetes, and CNS. It has strategically acquired companies across six continents to expand its global footprint. Some of its strengths include being a global leader in cephalosporin and anti-TB drugs, having a strong presence in over 70 countries, and being the largest generic player in the US and Japan.

    Original Title

    Lupin Pharmaceuticals Inc.pptx

    Copyright

    © © All Rights Reserved

    Available Formats

    PPTX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Lupin Limited is an Indian pharmaceutical company founded in 1968. It has manufacturing facilities in 18 countries and reaches over 70 countries with its generic drugs, branded drugs, and active pharmaceutical ingredients. The company has a strong presence in therapeutic areas like asthma, pediatrics, diabetes, and CNS. It has strategically acquired companies across six continents to expand its global footprint. Some of its strengths include being a global leader in cephalosporin and anti-TB drugs, having a strong presence in over 70 countries, and being the largest generic player in the US and Japan.

    Copyright:

    © All Rights Reserved
    Download as PPTX, PDF, TXT or read online from Scribd
    Download as pptx, pdf, or txt
    146 views10 pages

    Lupin Pharmaceuticals Inc

    Uploaded by

    Kishor Kshirasagar
    Lupin Limited is an Indian pharmaceutical company founded in 1968. It has manufacturing facilities in 18 countries and reaches over 70 countries with its generic drugs, branded drugs, and active pharmaceutical ingredients. The company has a strong presence in therapeutic areas like asthma, pediatrics, diabetes, and CNS. It has strategically acquired companies across six continents to expand its global footprint. Some of its strengths include being a global leader in cephalosporin and anti-TB drugs, having a strong presence in over 70 countries, and being the largest generic player in the US and Japan.

    Copyright:

    © All Rights Reserved
    Download as PPTX, PDF, TXT or read online from Scribd
    Download as pptx, pdf, or txt
    You are on page 1of 10
    At a glance
    Powered by AI
    Lupin Pharma is an Indian pharmaceutical company founded in 1968. It has presence in over 70 countries with key business in branded drugs, generics, APIs and manufacturing facilities across 18 countries.

    Lupin Pharma operates in branded drugs, generics, and APIs (Active Pharmaceutical Ingredients) segments.

    Some of the major acquisitions made by Lupin Pharma between 2007-2015 include Kyowa (Japan), Hormosan (Germany), Gavis (US), Pharma Dynamics (South Africa), Medquimica (Brazil), and Generic Health (Australia).

    Lupin Limited

    Company Analysis

    Group 9
    Kishor P Kshirasagar 1711327
    Mohd. Farhan Ansari 1711334
    Pratik Tamgadge 1711342
    Sujay Singh N M 1711360
    Vivek Dhaked 1711366
    Introduction to Lupin Pharma Inc.
    Founded in 1968 by Desh Bandhu Gupta
    Company reach to 70+ countries
    Business
     Branded drugs
     Generic Drugs
     Active Pharmaceutical Ingredients (API)
    Manufacturing facilities – 18 countries
    Awards 2017
     Ranked 1 – Biotech and Pharma
     Ranked 4 – Great place to work
    Evolution of Lupin Pharma Inc.
    1968 - Founded by Desh Bandhu Gupta

    1971 - Incorporated

    1980 - First R&D centre and manufacturing plant at Aurangabad

    1997-00 - Received approvals from UK MCA and US FDA for multiple drugs

    2000 - Lupin setup its state-of-art R&D centre in Pune

    2001 – Exports rose by 33% and crosses US$ 1 billion

    2007-15 – Multiple acquisitions across 6 continents like Kyowa (Japan), Hormosan (GER),
    Gavis (US), Pharma Dynamics (RSA), Medquimica (BRZ), Generic Health (AUS)

    2015 – Centre of Excellence for Inhalation Research, Florida, US


    Strategic Positioning
    Large Corporations

    1. Sun 1. Pfizer
    Pharma 2. Merck &
    2. Lupin Co.
    3. Dr. Reddy’s 3. Novartis AG
    Generic Drugs Specialized Drugs

    1. Aurobindo Glaxo Smith


    2. Glenmark Kline

    Small Corporations
    STRENGTH •WEAKNESS
    •Global leader in Cephalosporin & Anti TB drugs •Operates in low growth segment eg. respiratory
    •Strong presence in Asthma, Paediatrics, Diabetes, disorders, CNS, etc.
    and CNS •Japanese market is low margin business
    •Business in more than 70 countries •Dependency on global formulation business
    •Largest generic player in US and Japan primarily from the US

    •SWO
    •String of Small scale acquisitions

    OPPORTUNITIES
    T
    THREATS
    •Increased health awareness among public
    •Rising cost of raw materials
    •Emerging trends in the pharma industry
    •Increased scrutiny by USFDA regarding cGMP
    •TB still remains in the top 10 causes of deaths globally
    worldwide
    •Costly acquisitions can be an overhead if the
    •Opportunities in the oral contraceptive and product pipeline doesn't deliver expected payback
    respiratory space in the US generics market
    Competitive Strategy
    Business
    Strategy Industry Norm Competitive Advantage
    feature

    Heavy Investments in Research & Focus on new Major Market share in


    Innovation
    Development (R&D) drugs certain drug segments

    Focus on
    Global Manufacturing and Supply Vertical
    operational Cost effectiveness
    Chain Integration efficiency on
    Focus on
    Business
    Mergers & Acquisitions (M&A) inorganic Strategic Partnerships
    development
    growth
    Portfolio Strategic
    In-out licensing Enhanced market access
    enhancement agreements
    Competitive Advantage

    Major market share in certain drug segments

    Vertical Integration

    Strategic partnerships
    VRIN Analysis
    Resource/Capability V R I N Remarks

    Operational efficiency Competitive Parity

    Customer services Competitive Parity

    Effectiveness in executing sales Sustainable advantage

    Manufacturing and supply Sustainable advantage


    infrastructure
    VRIN Analysis
    Resource/Capability V R I N Remarks

    Innovation in new products / services Sustainable


    (R&D) advantage

    Competitive
    Proprietary technologies advantage

    temporary
    Strategic acquisition advantage

    Competitive
    Human Skills, expertise advantage
    Recommendations and Action Plan

    • Inorganic Expansion By Acquisition

    • Strategic Alliances For Faster And Economic Product Development

    • Developing Polypill Medicines

    • Personalized Medicine Using 3D Printing Technology

    You might also like